Does Acetyl-L-carnitine (ALCAR) affect the progression from prefrailty to frailty in older patients?
Acetyl-L-Carnitine, a randomized, double-blind, placebo-controlled trial in 92 subjects (Curr Pharm Des 2022, PMID 36043711) — compared to the placebo group, the ALCAR group exhibited a decrease in HDL cholesterol and CRP, and an increase in MMSE score and 6-minute walking distance. Scope: 92 subjects, over 3 months, and the abstract states no limitations.
Source: Curr Pharm Des 2022, PMID 36043711 ↗ · Research map · How Magellan grades evidence · evidence confidence: low
Curr Pharm Des · 2022 · PMID 36043711 · DOI 10.2174/1381612828666220830092815
Acetyl-L-carnitine supplementation may help slow the progression of prefrailty in older adults by improving cognitive function and physical performance.
The question
Does Acetyl-L-carnitine (ALCAR) affect the progression from prefrailty to frailty in older patients?
What they tested
The study aims to evaluate the effect of ALCAR in pre-frail older patients, suggesting a potential beneficial effect.
How they did it
This was a randomized, observational, double-blind, placebo-controlled study involving 92 subjects. Participants received either oral ALCAR (1.5 g twice daily) or a placebo for 3 months, followed by a 3-month follow-up period. Measurements included C-reactive protein (CRP), serum-free carnitine, acetylcarnitine, Mini-Mental State Examination (MMSE) scores, 6-minute walking distance, and HDL cholesterol.
What they found
After treatment, the ALCAR group showed a decrease in CRP and an increase in serum-free carnitine, acetylcarnitine, MMSE scores, and 6-minute walking distance. Compared to the placebo group, the ALCAR group exhibited a decrease in HDL cholesterol and CRP, and an increase in MMSE score and 6-minute walking distance.
| CRP (ALCAR vs. Placebo) | -1 | |
|---|---|---|
| HDL Cholesterol (ALCAR vs. Placebo) | -1 | |
| MMSE Score (ALCAR vs. Placebo) | 1 | |
| 6-Walking Distance (ALCAR vs. Placebo) | 1 |
This chart illustrates the direction of change in key markers in the ALCAR group compared to the placebo group. A value of 1 indicates an increase, and -1 indicates a decrease.
What it means
ALCAR treatment delays the incidence and severity of degenerative disorders in prefrail older subjects, improving memory and cognitive processes.
Limitations
The abstract does not explicitly state any limitations of the study.
Where the published abstract does not list limitations, we say so rather than inventing them. Read the full paper on PubMed before drawing conclusions.
The paper at a glance
| Title | Acetyl-L-carnitine Slows the Progression from Prefrailty to Frailty in Older Subjects: A Randomized Interventional Clinical Trial |
|---|---|
| Journal | Curr Pharm Des |
| Year | 2022 |
| PMID | 36043711 ↗ |
| DOI | 10.2174/1381612828666220830092815 ↗ |
| Topic | Brain, cognition & mood |
Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗
Where Magellan uses this paper
This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.
Acetyl-L-Carnitine (ALCAR)
Randomized trials and meta-analyses report modest benefits on cognition in mild cognitive impairment and mild Alzheimer's disease, on depressive symptoms — two meta-analyses (2018 and 2026) find efficacy comparable to antidepressants with fewer side effects, strongest in older adults — and on physical and mental…
Acetyl-L-carnitine (ALCAR) is the acetylated ester of the amino-acid derivative L-carnitine, a compound…
Research describes the compound or intervention studied. It is not a claim about any specific product.
Molecules & mechanisms in this paper
Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.
Cite this page
These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.
Magellan Longevity. (2026). Does Acetyl-L-carnitine (ALCAR) affect the progression from prefrailty to frailty in older patients? [Plain-English summary of Curr Pharm Des 2022, PMID 36043711, DOI 10.2174/1381612828666220830092815]. Magellan Longevity. https://magellanlongevity.com/study/d36043711.html@misc{magellan_d36043711,
title = {Does Acetyl-L-carnitine (ALCAR) affect the progression from prefrailty to frailty in older patients?},
author = {{Magellan Longevity}},
year = {2026},
howpublished = {\url{https://magellanlongevity.com/study/d36043711.html}},
note = {Plain-English summary of PubMed PMID 36043711; DOI 10.2174/1381612828666220830092815; Curr Pharm Des 2022. Reviewed by Gabriel Radu, DO},
urldate = {2026-08-11}
}https://magellanlongevity.com/study/d36043711.htmlRelated studies in the Magellan library
- Is Acetyl-l-carnitine (ALC) clinically effective in treating people with dementia?Cochrane Database Syst Rev · 2003 · PMID 12804452
- Does daily administration of cocoa extract (500 mg/day flavanols) or a commercial…Alzheimers Dement · 2022 · PMID 36102337
- Does MagteinPS, a formulation containing magnesium L-threonate, phosphatidylserine, and…Nutrients · 2022 · PMID 36558392
- Effects of Spermidine Supplementation on Cognition and Biomarkers in Older Adults With…JAMA Netw Open · 2022 · PMID 35616942
- Transcranial Near Infrared Light Stimulations Improve Cognition in Patients with DementiaAging Dis · 2021 · PMID 34221541
- Can luteolin improve memory deficits and reduce neuroinflammation in a triple-transgenic mouse…Acta Pharmacol Sin · 2021 · PMID 34267346
Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →